Cancer Treatment Reviews
Volume 25, Issue 6 , Pages 333-353 , December 1999

Cancer surgery: the last 25 years

  • A.J.A. Bremers

      Affiliations

    • Department of Oncologic Surgery, Leiden University Medical Center, Leiden, The Netherlands
    • ,
  • E.J.Th. Rutgers

      Affiliations

    • NKI/Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, The Netherlands
    • ,
  • C.J.H. van de Velde

      Affiliations

    • Department of Oncologic Surgery, Leiden University Medical Center, Leiden, The Netherlands

References 

    REFERENCES
  1. Hall JC, Platell C. Half-life of truth in surgical literature. Lancet. 1997;350:1752
  2. Lancet. 1999;353:1373
  3. Cady B. Basic principles in surgical oncology. Archives of Surgery. 1997;132:338–346
  4. Liefers GJ, Cleton-Jansen AM, van de Velde CJ. Micrometastases and survival in stage II colorectal cancer. New Eng J Med. 1998;339:223–228
  5. van den Akker-van Marle E, de Koning H, Boer R, van der Maas P. Reduction in breast cancer mortality due to the introduction of mass screening in The Netherlands: comparison with the United Kingdom. Journal of Medical Screening. 1999;6:30–34
  6. Sack H. [increasing incidence and declining mortality in breast carcinoma]. Strahlenther Onkol. 1997;173:388–389
  7. Newcomb PA, Lantz PM. Recent trends in breast cancer incidence, mortality, and mammography. Breast Cancer Res Treat. 1993;28:97–106
  8. Ursin G, Bernstein L, Pike MC. Breast cancer. Cancer Surv. 1994;19–20:241–264
  9. Gastrin G, Miller AB, To T. Incidence and mortality from breast cancer in the mama program for breast screening in finland, 1973–1986. Cancer. 1994;73:2168–2174
  10. Hanazaki K, Sodeyama H, Wakabayashi M. Surgical treatment of gastric cancer detected by mass screening. Hepatogastroenterology. 1997;44:1126–1132
  11. Robinson MH, Hardcastle JD. Should we be screening for colorectal cancer?. British Medical Bulletin. 1998;54:807–821
  12. Bond JH. Screening guidelines for colorectal cancer. American Journal of Medicine. 1999;106:7S–10S
  13. Anwar S, Hall C, Elder JB. Screening for colorectal cancer: present, past and future. Eur J Surg Oncol. 1998;24:477–486
  14. Burchert A, Schmassmann A. [Evaluation of various screening and surveillance methods in colorectal carcinoma]. Schweizerische Medizinische Wochenschrift. Journal Suisse de Me. 1998;999–1011
  15. Lennard-Jones JE. Is colonoscopic cancer surveillance in ulcerative colitis essential for every patient?. Eur J Cancer. 1995;31A:1178–1182
  16. Broome U, Lofberg R, Veress B, Eriksson LS. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology. 1995;22:1404–1408
  17. Rutgers EJ, van Slooten EA, Kluck HM. Follow-up after treatment of primary breast cancer. Br J Surg. 1989;76:187–190
  18. Stiggelbout AM, de Haes JC, Vree R. Follow-up of colorectal cancer patients: quality of life and attitudes towards follow-up. Br J Cancer. 1997;75:914–920
  19. JAMA. 1994;271:1587–1592
  20. Vrouenraets BC, Keus RB, Nieweg OE, Kroon BB. Complications of combined radiotherapy and isolated limb perfusion with tumor necrosis factor alpha +/– interferon gamma and melphalan in patients with irresectable soft tissue tumors. Journal of Surgical Oncology. 1997;65:88–94
  21. Nooijen PT, Eggermont AM, Schalkwijk L, Henzen-Logmans S, de Waal RM, Ruiter DJ. Complete response of melanoma-in-transit metastasis after isolated limb perfusion with tumor necrosis factor alpha and melphalan without massive tumor necrosis: a clinical and histopathological study of the delayed-type reaction pattern. Cancer Res. 1998;58:4880–4887
  22. de Vries MR, Rinkes IH, van de Velde CJ. Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: experimental studies in pigs and phase I data from humans. Rec Res Cancer Res. 1998;147:107–119
  23. Vahrmeijer AL, van der Eb MM, Van Dierendonck JH, Kuppen PJ, van de Velde CJ. Delivery of anticancer drugs via isolated hepatic perfusion: a promising strategy in the treatment of irresectable liver metastases?. Sem Surg Oncol. 1998;14:262–268
  24. Portilla AG, Sugarbaker PH, Chang D. Second-look surgery after cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: analysis of prognostic features. World J Surg. 1999;23:23–29
  25. Loggie BW, Fleming RA, Geisinger KR. Cytologic assessment before and after intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Acta Cytol. 1996;40:1154–1158
  26. Cintron JR, Pearl RK. Colorectal cancer and peritoneal carcinomatosis. [review] [17 refs]. Semin Surg Oncol. 1996;12:267–278
  27. Hill AD, Tran KN, Akhurst T. Lessons learned from 500 cases of lymphatic mapping for breast cancer. Ann Surg. 1999;229:528–535
  28. Bilchik AJ, Giuliano A, Essner R. Universal application of intraoperative lymphatic mapping and sentinel lymphadenectomy in solid neoplasms. Cancer J Sci Am. 1998;4:351–358
  29. Gershenwald JE, Thompson W, Mansfield PF. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage i or ii melanoma patients. J Clin Oncol. 1999;17:976–983
  30. Nieweg OE, Jansen L, Valdes Olmos RA. Lymphatic mapping and sentinel lymph node biopsy in breast cancer. European Journal of Nuclear Medicine. 1999;26:S11–16
  31. Bremers AJ, Kuppen PJ, Parmiani G. Tumour Immunotherapy: the adjuvant treatment of the 21st century?. [In Press] Eur J Surg Oncol. 2000;
  32. Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going?. J Natl Cancer Inst. 1997;89:21–39
  33. van der Eb MM, Hoeben RC, van de Velde CJ. Towards gene therapy for colorectal liver metastases. Rec Res Cancer Res. 1998;147:173–186
  34. Hollingsworth SJ, Barker SGE. Gene therapy: into the future of surgery. Lancet. 1999;353:SI 19, S120
  35. Ursin G, Bernstein L, Pike MC. Breast cancer. Cancer Surv. 1994;19/20:241, ???
  36. Nystrom L, Rutqvist LE, Wall S. Breast cancer screening with mammography: overview of swedish randomised trials. Lancet. 1993;341:973–978
  37. Wright CJ, Mueller CB. Screening mammography and public health policy: the need for perspective. Lancet. 1995;346:29–32
  38. de Koning HJ, Boer R, Warmerdam PG, Beemsterboer PM, van der Maas PJ. Quantitative interpretation of age-specific mortality reductions from the swedish breast cancer-screening trials. J Natl Cancer Inst. 1995;87:1217–1223
  39. de Koning HJ, Fracheboud J, Boer R. Nation-wide breast cancer screening in the netherlands: support for breast-cancer mortality reduction. national evaluation team for breast cancer screening. Int J Cancer. 1995;60:777–780
  40. Dixon JM, Ravisekar O, Cunningham M, Anderson ED, Anderson TJ, Brown HK. Factors affecting outcome of patients with impalpable breast cancer detected by breast screening. Br J Surg. 1999;997–1001
  41. Blichert-Toft M. The axilla: to clear or not to clear? That is the question. Rec Res Cancer Res. 1998;152:149–160
  42. Cady B. Case against axillary lymphadenectomy for most patients with infiltrating breast cancer. Journal of Surgical Oncology. 1997;66:7–10
  43. Epstein RJ. Routine or delayed axillary dissection for primary breast cancer?>…. Eur J Cancer. 1995;31A:1570–1573
  44. O’Higgins N, Linos DA, Blichert-Toft M. European guidelines for quality assurance in the surgical management of mammographically detected lesions. Eur J Surg Oncol. 1998;24:96–98
  45. Woodcock NP, Glaves I, Morgan DR, MacFie J. Ultrasound-guided tru-cut biopsy of the breast. Ann R Coll Surg Engl. 1998;80:253–256
  46. Phillips G, McGuire L, Clowes D. The value of ultrasound-guided fine needle aspiration in the assessment of solid breast lumps. Australas Radiol. 1994;38:187–192
  47. Bonnema J, van Geel AN, van Ooijen B. Ultrasound-guided aspiration biopsy for detection of nonpalpable axillary node metastases in breast cancer patients: new diagnostic method. –. World J Surg. 1997;21(3):270–274
  48. Boetes C, Strijk SP, Holland R, Barentsz JO, Van Der Sluis RF, Ruijs JH. False-negative MR imaging of malignant breast tumors. Eur Radiol. 1997;7(8):1231–1234
  49. Friedrich M. MRI of the breast: state of the art. Eur Radiol. 1998;8:707–725
  50. Kramer S, Schulz-Wendtland R, Hagedorn K, Bautz W, Lang N. Magnetic resonance imaging in the diagnosis of local recurrences in breast cancer. Anticancer Res. 1998;18:2159–2161
  51. Harms SE. Breast magnetic resonance imaging. Semin Ultrasound CT MR. 1998;19:104–120
  52. Heywang-Kobrunner SH, Viehweg P, Heinig A. Contrast-enhanced MRI of the breast: accuracy, value, controversies, solutions. Eur J Radiol. 1997;24:94–108
  53. Taillefer R. The role of 99mtc-sestamibi and other conventional radiopharmaceuticals in breast cancer diagnosis. Semin Nucl Med. 1999;29:16–40
  54. Veronesi U, Saccozzi R, Del Vecchio M. Comparing radical mastectomy with quandrantectomy, axillary dissection and radiotherapy in patients with small cancers of the breast. New Eng J Med. 1981;305:6–11
  55. Veronesi U, Luini A, Galimberti V. Conservation approaches for the management of stage I/II carcinoma of the breast: Milan Cancer Institute Trials. World Journal of Surgery. 1994;18:70–75
  56. Fisher B, Redmond C, Poisson R. Eight year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. New Eng J Med. 1989;320:822–828
  57. Jacobson JA, Danforth DN, Cowan KH. Ten-year results of a comparison of conservation with mastectomyin the treatment of stage I and II breast cancer. New Eng J Med. 1995;332:907–911
  58. Arriagada R, Le MG, Rochard F. Conservative treatment versus mastectomy in early breast cancer: Patterns of failure with 15 years of follow-up data. J Clin Oncol. 1996;14:1558–1564
  59. van Dongen JA, Bartelink H, Fentiman IS. Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer: EORTC 10801 trial. J Natl Cancer Inst. 1992;11:15–18
  60. Blichert-Toft M, Rose C, Andersen JA. Danish randomized trial comparing breast conservation therapy with mastectomy: Six years of life-table analysis. J Natl Cancer Inst Monogr. 1992;11:19–25
  61. Liljegren G, Lindgren A, Bergh J, Nordgren H, Tabar L, Holmberg L. Risk factors for local recurrence after conservative treatment in stage i breast cancer. definition of a subgroup not requiring radiotherapy. Ann Oncol. 1997;8:235–241
  62. Salvadori B. Local recurrences after breast-conserving treatment: an open problem. Semin Surg Oncol. 1996;12:46–52
  63. Mauriac L, MacGrogan G, Avril A. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124 month median follow-up. Annals of Oncology. 1999;10:47–52
  64. Kuerer HM, Newman LA, Smith TL. Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy. J Clin Oncol. 1999;17:460–469
  65. Zurrida S, Greco M, Veronesi U. Surgical pitfalls after preoperative chemotherapy in large size breast cancer. Eur J Surg Oncol. 1994;20:641–643
  66. Veronesi U, Bonadonna G, Zurrida S. Conservation surgery after primary chemotherapy in large carcinomas of the breast. Ann Surg. 1995;222:612–618
  67. Honkoop AH, Wagstaff J, Pinedo HM. Management of stage iii breast cancer. Oncology. 1998;55:218–227
  68. Bates T, Riley DL, Houghton J, Fallowfield L, Baum M. Breast cancer in elderly women: a cancer research campaign trial comparing treatment with tamoxifen and optimal surgery with tamoxifen alone. the elderly breast cancer working party. Br J Surg. 1991;78:591–594
  69. Richards MA, Smith P, Ramirez AJ, Fentiman IS, Rubens RD. The influence on survival of delay in the presentation and treatment of symptomatic breast cancer. Br J Cancer. 1999;79:858–864
  70. Fisher ER, Sass R, Fisher B. Pathologic findings from the national surgical adjuvant project for breast cancers (protocol no.4). x. discriminants for tenth year treatment failure. Cancer. 1984;53:: 712, 23
  71. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24, 740 breast cancer cases. Cancer. 1989;63:181–187
  72. JAMA. 1991;265:391–395
  73. Lancet. 1998;352:930–942
  74. Overgaard M. Postoperative radiotherapy in high-risk premenopauzal women with breast cancer who receive adjuvant chemotherapy. New Eng J Med. 1997;337:949–955
  75. Keramopoulos A, Tsionou C, Minaretzis D, Michalas S, Aravantinos D. Arm morbidity following treatment of breast cancer with total axillary dissection: a multivariated approach. Oncology. 1993;50:445–449
  76. Ivens D, Hoe AL, Podd TJ, Hamilton CR, Taylor I, Royle GT. Assessment of morbidity from complete axillary dissection. Br J Cancer. 1992;66:136–138
  77. Kissin MW, Querci della Rovere G, Easton D, Westbury G. Risk of lymphoedema following the treatment of breast cancer. Br J Surg. 1986;73:580–584
  78. Rutgers EJ, Peterse HL. Future prospects for the staging of breast cancer. Semin Surg Oncol. 1996;12:3–11
  79. Hsueh EC. J Amer Coll Surg. 1999;189:207–213
  80. Nieweg OE, Rutgers EJ. World Journal of Surgery. 1999;
  81. Cabanas RM. An approach for the treatment of penile carcinoma. Cancer. 1977;39:456–466
  82. Morton DL, Wen DR, Wong JH. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392–399
  83. Cancer. 1997;80:1798–1802
  84. Gupta SK, Douglas-Jones AG, Fenn N, Morgan JM, Mansel RE. The clinical behavior of breast carcinoma is probably determined at the preinvasive stage (ductal carcinoma in situ). Cancer. 1997;80:1740–1745
  85. Holland R, Hendriks JH, Vebeek AL, Mravunac M, Schuurmans Stekhoven JH. Extent, distribution, and mammographic/histological correlations of breast ductal carcinoma in situ. Lancet. 1990;335:519–522
  86. Silverstein MJ, Lagios MD, Groshen S. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med. 1999;340:1455–1461
  87. Fisher ER, Costantino J, Fisher B, Palekar AS, Redmond C, Mamounas E. Pathologic findings from the national surgical adjuvant breast project (nsabp) protocol b-17. intraductal carcinoma (ductal carcinoma in situ). the national surgical adjuvant breast and bowel project collaborating investigators. Cancer. 1995;75:1310–1319
  88. Fentiman IS. Trials of treatment for non-invasive breast cancer. Recent Results Cancer Res. 1998;152:135–142
  89. Fisher B, Dignam J, Wolmark N. Tamoxifen in treatment of intraductal breast cancer: national surgical adjuvant breast and bowel project b-24 randomised controlled trial. Lancet. 1999;353:1993–2000
  90. Ford D, Easton DF, Stratton M. Genetic heterogeneity and penetrance analysis of the brca1 and brca2 genes in breast cancer families. the breast cancer linkage consortium. Am J Hum Genet. 1998;62:676–689
  91. Stefanek ME. Bilateral prophylactic mastectomy: issues and concerns. J Natl Cancer Inst Monogr. 1995;37–42
  92. Mann GB, Borgen PI. Breast cancer genes and the surgeon. J Surg Oncol. 1998;67:267–274
  93. Kennedy EP, Hamilton SR. Genetics of colorectal cancer. Semin Surg Oncol. 1998;15:126–130
  94. Herfarth C, Heuschen G, Heuschen UA. [Malignant transformation in ulcerative colitis and surgical implications]. Chirurg. 1998;69:1020–1027
  95. Moynihan BG. The surgical treatment of cancer of the sigmoid flexure and rectum: with special attention to the principles observed. Surg Gynec Obs. 1908;6:463–466
  96. Miles WE. A method of performing abdomino-perineal resection for carcinoma of the rectum and of the terminal portion of the pelvic colon. Lancet. 1908;11:1812–1813
  97. Miles, W. E. AnonymousLettsomiam Lectures. Cancer of the Rectum, London, Harrison and Sons, 1923
  98. Best RR, Blair JB. Sphincter preserving operations for rectal carcinoma as related to the anatomy of the lymphatics. Ann Surg. 1949;130:538–576
  99. Grinnell RS. Distal intramural spread of carcinoma of the rectum and rectosigmoid. Surg Gynec Obs. 1954;99:421–430
  100. Williams NS, Dixon MF, Johnston D. Reappraisal of the 5 centimetre rule of distal excision for carcinoma of the rectum: a study of distal intramural spread and of patients’ survival. Brit J Surg. 1983;70:150–154
  101. Andreola S, Leo E, Belli F. Distal intramural spread in adenocarcinoma of the lower third of the rectum treated with total rectal resection and coloanal anastomosis. Dis Colon Rectum. 1997;40:25–29
  102. Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery – the clue to pelvic recurrence?. Brit J Surg. 1982;69:613–616
  103. Heald RJ. Rectal Cancer: the surgical options. Eur J Cancer. 1995;31A:1189–1192
  104. Lloyd-Davies OV. Radical excision of carcinoma of the rectum with conservation of the sphincters. Proc Natl Acad Sci USA. 1948;41:822–826
  105. Karanjia ND, Corder AP, Bearn P, Heald RJ. Leakage from stapled low anastomosis after total mesorectal excision for carcinoma of the rectum. Brit J Surg. 1994;81:1224–1226
  106. Heald, R. J.Soreide, O.Norstein, J. Rectal Cancer Surgery. Berlin/Heidelberg, Springer, 1997, 15, Total Mesorectal Excision: History and Anatomy of an Operation, 203, 19
  107. McCall JL, Cox MR, Wattchow DA. Analysis of local recurrence rates after surgery alone for rectal cancer. Int J Colorectal Dis. 1995;10:126–132
  108. Dahlberg M, Glimelius B, Pahlman L. Improved survival and reduction in local failure rates after preoperative radiotherapy: evidence for the generalizability of the results of swedish rectal cancer trial. Ann Surg. 1999;229:493–497
  109. Turnbull RB, Kyle K, Watson FR. Cancer of the colon; the influence of the no-touch isolation technique on survival rates. Ann Surg. 1968;18:82–88
  110. Wiggers T, Jeekel J, Arends JW. The no-touch isolation technique in colon cancer: a prospective controlled multicentre trial. Brit J Surg. 1985;75:409–415
  111. Michelassi F, Vannuci L, Alaya JA, Chappel R, Goldberg R, Block GE. Local recurrence after curative resection of colorectal carcinoma. Surgery. 1990;108:787–792
  112. Schlag PM, Benhidjeb T, Kilpert B. [Principles of curative resection of liver metastases]. Chirurg. 1999;70:123–132
  113. Yamamoto J, Shimada K, Kosuge T, Yamasaki S, Sakamoto M, Fukuda H. Factors influencing survival of patients undergoing hepatectomy for colorectal metastases. Brit J Surg. 1999;86:332–337
  114. Chen HS, Gross JF. Intra-arterial infusion of anticancer drug: theoretic aspects of drug delivery and review of responses. Cancer treatment rep. 1980;64:31–40
  115. Laufman L, Nims T, Guy JT, Guy JF, Courter S. Hepatic arterial ligation and portal vein infusion for liver metastases from colorectal cancer. J Clin Oncol. 1984;2:1382–1389
  116. van de Velde, C. J.Tjaden, U. R.Kothuis, B. J.L.van de Velde, C. J.Sugarbaker, P. Liver metastases. Isolated regional liver perfusion in the treatment of hepatic metastases. Amsterdam, Nijhoff, 1984
  117. Kuppen PJ, Jonges LE, van de Velde CJ. Liver and tumour tissue concentrations of TNF-alpha in cancer patients treated with TNF-alpha and melphalan by isolated liver perfusion. Brit J Cancer. 1997;75:1497–1500
  118. Marinelli A, de Brauw LM, Beerman H. Isolated liver perfusion with mitomycin C in the treatment of colorectal cancer metastases confined to the liver. Jap J Clin Onc. 1996;26:341–350
  119. JAMA. 1990;264:1444–1450
  120. Moertel CG, Fleming TR, MacDonald JS. Levamisole and fluorouracil for adjuvant therapy of resectedcolon carcinoma. New Eng J Med. 1990;322:352–356
  121. Stamos MJ. Colon and Rectal Surgery. J Amer Coll Surg. 1998;186:134–140
  122. Bremers AJ, Parmiani G. Immunotherapy for colon cancer. Lancet. 1999;353:1524–1525
  123. Vermorken JB, Claessen AM, van Tinteren H. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet. 1999;353:345–350
  124. Hoover HC, Brandhorst JS, Peters LC. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol. 1993;11:390–399
  125. Schlag P, Manasterski M, Gerneth T. Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial. Cancer Immunol Immunother. 1992;35:325–330
  126. Riethmueller G, Holz E, Schlimok G. Monoclonal antibody therapy for resected Dukes’ C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol. 1998;16:1788–1794
  127. Macintyre IM, Akoh JA. Improving survival in gastric cancer: review of operative mortality in English language publications from 1970. Brit J Surg. 1991;78:771–776
  128. Akoh JA, Macintyre IM. Improving survival in gastric cancer: review of 5-year survival rates in English language publications from 1970. Brit J Surg. 1992;79:293–299
  129. Woelfler A. Ueber die Herrn Professor Billroth ausgefuehrten Resectionen des carcinomatoesen Pylorus. Anonymous. 1881;
  130. Mikulicz J. Beitrage zur Technik der Operation des Magencarcinoms. Arch Klin Chir Berl. 1898;1:524–532
  131. Cunéo D. De l’envahissement du système lymphatique dans le cancer de l’estomac et de ses consequences chirurgicales. Anonymous. 1900;
  132. Jamieson JK, Dobson JF. The lymphatic system of the stomach. Lancet. 1907;1061–1066
  133. Pack GT, McNeer GP. Total gastrectomy for cancer: a collective review of the literature and an original repor on 20 cases. Internat Abstr Surg. 1943;77:265–299
  134. Eker R. Carcinoma of the stomach. Investigation of the lymphatic spread from gastric carcinomas after total and partial gastrectomy. Act Chir Scand. 1951;101:112–126
  135. Kampschoer GH, Fujii A, Masuda Y. Gastric cancer detected by mass survey. Comparison between mass survey and outpatient detection. Scandinavian Journal of Gastroenterology. 1989;24:813–817
  136. Kajitani T. The general rules for the gastric cancer study in surgery and pathology. Part I. Clinical classification. Japanese Journal of Surgery. 1981;11:127–139
  137. Kinoshita, T. Maruyama, K. Sasako, M. Nishi, M.Ichakawa, H.Nakajima, T.Maruyama, K.Tahara, E. Gastric cancer. Treatment results of gastric cancer patients: Japanese experience, Tokyo/Berlin/Heidelberg, Springer Verlag, 1993
  138. Wanebo HJ, Kennedy BJ, Chmiel J, Steele G, Winchester D, Osteen R. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg. 1993;218:583–592
  139. Maruyama K, Gunven P, Okabayashi K, Sasako M, Kinoshita T. Lymph node metastases of gastric cancer. General pattern in 1931 patients. Ann Surg. 1989;210:596–602
  140. Cuschieri A. Recent advances in gastrointestinal malignancy. Ann Chir Gynaec. 1989;78:228–237
  141. Bonenkamp JJ, van de Velde CJ, Kampschoer GH. Comparison of factors influencing the prognosis of Japanese, German, and Dutch gastric cancer patients. World Journal of Surgery. 1993;17:410, 4; discussion 415
  142. Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ. Extended lymph-node dissection for gastric cancer. Dutch Gastric Cancer Group. New Eng J Med. 1999;340:908–914
  143. Dent DM, Madden MV, Price SK. Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. Brit J Surg. 1988;75:110–112
  144. Robertson CS, Chung SC, Woods SD. A prospective randomized trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer. Ann Surg. 1994;220:176–182
  145. Bonenkamp JJ, Songun I, Hermans J. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet. 1995;345:745–748
  146. Cuschieri A, Fayers P, Fielding J. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet. 1996;347:995–999
  147. Cuschieri A, Weeden S, Fielding J. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Brit J Cancer. 1999;79:1522–1530
  148. Viste A, Haugstvedt T, Eide GE, Soreide O. Postoperative complications and mortality after surgery for gastric cancer. Ann Surg. 1988;207:7–13
  149. Bottcher K, Siewert JR, Roder JD, Busch R, Hermanek P, Meyer HJ. [Risk of surgical therapy of stomach cancer in Germany. Results of the German 1992 Stomach Cancer Study. German Stomach Cancer Study Group (′92)]. Chirurg. 1994;65:298–306
  150. Gennari L, Bozzetti F, Bonfanti G. Subtotal versus total gastrectomy for cancer of the lower two-thirds of the stomach: a new approach to an old problem. Brit J Surg. 1986;73:534–538
  151. Sasako M. Risk factors for surgical treatment in the Dutch Gastric Cancer Trial. Brit J Surg. 1997;84:1567–1571
  152. Bozzetti F, Marubini E, Bonfanti G. Total versus subtotal gastrectomy: surgical morbidity and mortality rates in a multicenter Italian randomized trial. The Italian Gastrointestinal Tumor Study Group. Ann Surg. 1997;226:613–620
  153. Kodera Y, Yamamura Y, Shimizu Y. Lack of benefit of combined pancreaticosplenectomy in D2 resection for proximal-third gastric carcinoma. World Journal of Surgery. 1997;21:622, 7; discussion 627.8
  154. Kitamura K, Nishida S, Ichikawa D. No survival benefit from combined pancreaticosplenectomy and total gastrectomy for gastric cancer. Brit J Surg. 1999;86:119–122
  155. Viste A, Svanes K, Janssen CW, Maartmann-Moe H, Soreide O. Prognostic importance of radical lymphadenectomy in curative resections for gastric cancer. European Journal of Surgery. 1994;160:497–502
  156. Griffith JP, Sue-Ling HM, Martin I. Preservation of the spleen improves survival after radical surgery for gastric cancer. Gut. 1995;36:684–690
  157. Arak A, Kull K. Factors influencing survival of patients after radical surgery for gastric cancer. A regional study of 406 patients over a 10-year period. Acta Oncologica. 1994;33:913–920
  158. Lisborg P, Jatzko G, Horn M. Radical surgery (R2 resection) for gastric cancer. A multivariate analysis. Scandinavian Journal of Gastroenterology. 1994;29:1024–1028
  159. Roukos DH, Lorenz M, Encke A. Evidence of survival benefit of extended (D2) lymphadenectomy in western patients with gastric cancer based on a new concept: a prospective long-term follow-up study. Surgery. 1998;123:573–578
  160. Degiuli M, Sasako M, Ponzetto A. Extended lymph node dissection for gastric cancer: results of a prospective, multi-centre analysis of morbidity and mortality in 118 consecutive cases. Eur J Surg Oncol. 1997;23:310–314
  161. Brady MS, Rogatko A, Dent LL, Shiu MH. Effect of splenectomy on morbidity and survival following curative gastrectomy for carcinoma. Archives of Surgery. 1991;126:359–364
  162. Aldridge MC, Williamson RC. Distal pancreatectomy with and without splenectomy. Brit J Surg. 1991;78:976–979
  163. Kaneda M, Horimi T, Ninomiya M. Adverse affect of blood transfusions on survival of patients with gastric cancer. Transfusion. 1987;27:375–377
  164. Sugezawa A, Kaibara N, Sumi K. Blood transfusion and the prognosis of patients with gastric cancer. Journal of Surgical Oncology. 1989;42:113–116
  165. Sasako M, McCulloch P, Kinoshita T, Maruyama K. New method to evaluate the therapeutic value of lymph node dissection for gastric cancer. Brit J Surg. 1995;82:346–351
  166. Bollschweiler E, Boettcher K, Hoelscher AH. Preoperative assessment of lymph node metastases in patients with gastric cancer: evaluation of the Maruyama computer program. Brit J Surg. 1992;79:156–160
  167. Boku T, Nakane Y, Minoura T. Prognostic significance of serosal invasion and free intraperitoneal cancer cells in gastric cancer. Brit J Surg. 1990;77:436–439
  168. Nakajima T, Harashima S, Hirata M, Kajitani T. Prognostic and therapeutic values of peritoneal cytology in gastric cancer. Acta Cytologica. 1978;22:225–229
  169. Bonenkamp JJ, Songun I, Hermans J, van de Velde CJ. Prognostic value of positive cytology findings from abdominal washings in patients with gastric cancer. Brit J Surg. 1996;83:672–674
  170. Damhuis RA, Tilanus HW. The influence of age on resection rates and postoperative mortality in 2773 patients with gastric cancer. Eur J Cancer. 1995;31A:928–931
  171. Kranenbarg EK, van de Velde CJ. Gastric cancer in the elderly. Eur J Surg Oncol. 1998;24:384–390
  172. McCulloch P. D1 versus D2 dissection for gastric cancer. Lancet. 1995;345:1516, 7; discussion 1517.8
  173. Parikh D, Johnson M, Chagla L, Lowe D, McCulloch P. D2 gastrectomy: lessons from a prospective audit of the learning curve. Brit J Surg. 1996;83:1595–1599
  174. McCulloch P. Should general surgeons treat gastric carcinoma? An audit of practice and results, 1980–1985. Brit J Surg. 1994;81:417–420
  175. Bonenkamp JJ, van de Velde CJ, Sasako M, Hermans J. R2 compared with R1 resection for gastric cancer: morbidity and mortality in a prospective, randomised trial. European Journal of Surgery. 1992;158:413–418
  176. Bozzetti F, Bonfanti G, Audisio RA. Prognosis of patients after palliative surgical procedures for carcinoma of the stomach. Surg Gynec Obs. 1987;164:151–154
  177. Haugstvedt T, Viste A, Eide GE, Soreide O. The survival benefit of resection in patients with advanced stomach cancer: the Norwegian multicenter experience. Norwegian Stomach Cancer Trial. World Journal of Surgery. 1989;13:617, 21; discussion 621.2
  178. Meijer S, De Bakker OJ, Hoitsma HF. Palliative resection in gastric cancer. Journal of Surgical Oncology. 1983;23:77–80
  179. Monson JR, Donohue JH, McIlrath DC, Farnell MB, Ilstrup DM. Total gastrectomy for advanced cancer. A worthwhile palliative procedure. Cancer. 1991;68:1863–1868
  180. MacDonald JS, Woolley PV, Smythe T, Ueno W, Hoth D, Schein PS. 5-fluorouracil, adriamycin, and mitomycin-C (FAM) combination chemotherapy in the treatment of advanced gastric cancer. Cancer. 1979;44:42–47
  181. Hermans J, Bonenkamp JJ, Boon MC. Author update of adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. [In Press] J Clin Oncol. 1999;
  182. Hermans J, Bonenkamp JJ, Boon MC. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol. 1993;11:1441–1447
  183. Ellis, P.Cunningham D; Sigamura, T.Sasako, M. Gastric Cancer. Adjuvant and neoadjuvant chemotherapy, Oxford/New York/Tokyo, Oxford University Press, 1997
  184. Takahashi K, Harauchi D, Kimura S, Saito S, Monden Y. OK-432 develops CTL and LAK activity in mononuclear cells from regional lymph nodes of lung cancer patients. Int J Immunopharm. 1998;20:375–388
  185. Kim JP, Kwon OJ, Oh ST, Yang HK. Results of surgery on 6589 gastric cancer patients and immunochemosurgery as the best treatment of advanced gastric cancer. Ann Surg. 1992;216:269, 78; discussion 278.9
  186. Norris W. Case of fungoid disease. Edinburgh Medical and Surgical Journal. 1820;16:562
  187. Coats J. On a case of multiple melanotic sarcoma. Glasgow Medical Journal. 1885;24:92
  188. Handley WS. The pathology of melanotic growths in relation to their operative treatment. Lancet. 1907;927:99
  189. Clark, W. H. London, Pergamom, 1967, A classification of malignant melanoma in man correlated with histogenesis and biological behavior. 621, 45
  190. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970;172:902–908
  191. Veronesi U, Cascinelli N, Adamus J. Narrow excision (1 cm margin): a safe procedure for thin cutaneous melanoma. Results of an international randomizedtrial. Archives of Surgery. 1991;126:438–441
  192. Balch CM, Urist MM, Karakousis CP. Efficacy of 2-cm surgical margins for intermediate thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg. 1993;218:262–267
  193. Jonk A, Kroon BB, Rumke P, van der Esch EP, Hart AA. Results of radical dissection of the groin in patients with stage II melanoma and histologically proved metastases of the iliac or obturator lymph nodes, or both. Surg Gynec Obs. 1988;167:28–32
  194. Karakousis CP, Emrich LJ, Driscoll DL, Rao U. Survival after groin dissection for malignant melanoma. Surgery. 1991;109:119–126
  195. Coit DG, Brennan MF. Extent of lymph node dissection in melanoma of the trunk or lower extremity. Archives of Surgery. 1989;124:162–166
  196. Eve F. A lecture on melanoma. Practitioner. 1903;70:165
  197. Veronesi U, Adamus J, Bandiera DC. Inefficacy of immediate node dissection in stage I melanoma of the limbs. New Eng J Med. 1977;297:627
  198. Sim FH, Taylor WF, Pritchard DJ, Soule EH. Lymphadenectomy in the management of stage i malignant melanoma: a prospective randomized study. Mayo Clin Proc. 1986;61:697–705
  199. Balch CM, Soong SJ, Bartolucci AA. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg. 1996;224:255–263
  200. Morton DL. Sentinel lymphadenectomy for patients with clinical stage i melanoma. J Surg Oncol. 1997;66:267–269
  201. Stehlin JS. Hyperthermic perfusion with chemotherapy for cancers of the extremities. Surg Gynec Obs. 1969;129:305–308
  202. Thompson JF, Hunt JA, Shannon KF, Kam PC. Frequency and duration of remission after isolated limb perfusion for melanoma. Archives of Surgery. 1997;132:903–907
  203. Taber SW, Polk HC. Mortality, major amputation rates, and leukopenia after isolated limb perfusion with phenylalanine mustard for the treatment of melanoma. Ann Surg Oncol. 1997;4:440–445
  204. Koops HS, Vaglini M, Suciu S. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol. 1998;16:2906–2912
  205. Manusama ER, Nooijen PT, Ten Hagen TL. Tumor necrosis factor-alpha in isolated perfusion systems in the treatment of cancer: the Rotterdam preclinical-clinical program. Sem Surg Oncol. 1998;14:232–237
  206. Lienard D, Eggermont AM, Kroon BB, Schraffordt Koops H, Lejeune FJ. Isolated limb perfusion in primary and recurrent melanoma: indications and results. Sem Surg Oncol. 1998;14:202–209
  207. Agarwala SS, Kirkwood JM. Adjuvant interferon treatment for melanoma. Hematology – Oncology Clinics of North America. 1998;12:823–833
  208. Pehamberger H, Soyer HP, Steiner A. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol. 1998;16:1425–1429
  209. Grob JJ, Dreno B, de la Salmoniere P. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet. 1998;351:1905–1910
  210. Eggermont AM. The current EORTC Melanoma Cooperative Group adjuvant trial programme on malignant melanoma: prognosis versus efficacy, toxicity and costs. Melanoma Res. 1997;7 Suppl 2:S127–131
  211. Elias EG, Suter CM, Fabian DS. Adjuvant immunotherapy in melanoma with irradiated autologous tumor cells and low dose cyclophosphamide. Journal of Surgical Oncology. 1997;64:17–22
  212. Rosenberg SA, Yannelli JR, Yang JC. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst. 1994;86:1159–1166

PII: S0305-7372(99)90147-0

doi: 10.1053/ctrv.1999.0147

Cancer Treatment Reviews
Volume 25, Issue 6 , Pages 333-353 , December 1999

Article Tools